DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Bjartell AS, Ye D, Agarwal N. et al.
Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis.
EAU20 Virtual 2020;
41: 556
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.